Case reportIntractable Recurrent Hepatitis A Virus Infection Requiring Repeated Liver Transplantation: A Case Report
Section snippets
Case Presentation
A 40-year-old man was admitted to our institution with acute hepatic failure. Blood biochemical profiles showed the following: alanine aminotransferase concentration, 6992 IU/L; aspartate aminotransferase concentration, 9224 IU/L; total bilirubin concentration, 10.3 mg/dL; γ-glutamyl transferase concentration, 250 IU/L; alkaline phosphatase concentration, 192 IU/L; prothrombin time International Normalized Ratio, 5.88; ammonia concentration, 160 μmol/L; and creatinine concentration, 7.7 mg/dL.
Discussion
The natural course of HAV infection usually consists of a self-limiting acute hepatitis of varying intensity leading to life-long protective immunity. The incubation time of the virus is approximately 4 weeks before the onset of clinical disease characterized by jaundice and increased transaminase levels. Disease intensity can vary, from subclinical to severe hepatitis, occasionally with a pronounced cholestatic phenotype.4 Infectivity has been regarded as limited to the presymptomatic period
References (11)
- et al.
Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction
Hepatology
(1996) - et al.
Clinical recurrence of hepatitis A following liver transplantation for acute liver failure
J Med Virol
(1995) - et al.
Relapsing hepatitis AReview of 14 cases and literature survey
Medicine (Baltimore)
(1992) - et al.
The persistence of hepatitis A IgM antibody after acute clinical hepatitis A
Hepatology
(1984) Hepatitis A: old and new
Clin Mircrobiol Rev
(2001)
Cited by (11)
Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system
2018, Antiviral ResearchCitation Excerpt :Clinically, sofosbuvir is shown to be promising for the treatment of HCV persistently-infected patients who are post-liver-transplant since IFN treatment is not suitable due to accelerated allograft injury (Fontana et al., 2013; Stedman, 2014). For HAV infected patients who undergo liver transplantation (Fagan et al., 1990; Park et al., 2010), sofosbuvir treatment may be helpful to prevent recurrent HAV infection. Further evaluation of sofosbuvir on its efficacy and safety in an animal model is necessary.
Histopathology of Liver Transplantation
2015, Transplantation of the Liver: Third EditionLiver transplant evaluation for fulminant liver failure due to acute hepatitis A infection: Case series and literature review
2021, Transplant Infectious DiseaseHepatitis A Infections in Transplant
2021, Emerging Transplant Infections: Clinical Challenges and ImplicationsHepatitis A virus infection in an HIV-positive man with previously confirmed immunity against hepatitis A virus
2020, Clinical Journal of Gastroenterology